Your browser doesn't support javascript.
loading
Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset.
Elkhalifa, Marwa; Orbai, Ana-Maria; Magder, Laurence S; Petri, Michelle; Alarcón, Graciela S; Gordon, Caroline; Merrill, Joan; Fortin, Paul R; Bruce, Ian N; Isenberg, David; Wallace, Daniel; Nived, Ola; Ramsey-Goldman, Rosalind; Bae, Sang-Cheol; Hanly, John G; Sanchez-Guerrero, Jorge; Clarke, Ann E; Aranow, Cynthia; Manzi, Susan; Urowitz, Murray; Gladman, Dafna D; Kalunian, Ken; Werth, Victoria P; Zoma, Asad; Bernatsky, Sasha; Khamashta, Munther; Jacobsen, SØren; Buyon, Jill P; Dooley, Mary Anne; Vollenhoven, Ronald van; Ginzler, Ellen; Stoll, Thomas; Peschken, Christine; Jorizzo, Joseph L; Callen, Jeffery P; Lim, Sam; Inanc, Murat; Kamen, Diane L; Rahman, Anisur; Steinsson, Kristjan; Franks, Andrew G.
Affiliation
  • Elkhalifa M; Department of Medicine, Alexandria University, Alexandria, Egypt.
  • Orbai AM; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Magder LS; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Petri M; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Alarcón GS; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Gordon C; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Merrill J; Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Fortin PR; Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
  • Bruce IN; Division of Rheumatology, CHU de Québec - Université Laval, Quebec City, Canada.
  • Isenberg D; Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospital NHS Foundation Trust, Manchester Academic Health Science Center, Ma
  • Wallace D; Centre for Rheumatology Research, University College, London, UK.
  • Nived O; Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Ramsey-Goldman R; Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Bae SC; Northwestern University and Feinberg School of Medicine, Chicago, IL, USA.
  • Hanly JG; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.
  • Sanchez-Guerrero J; Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Clarke AE; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
  • Aranow C; Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Manzi S; Feinstein Institute for Medical Research, Manhasset, NY, USA.
  • Urowitz M; Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, USA.
  • Gladman DD; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
  • Kalunian K; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
  • Werth VP; UCSD School of Medicine, La Jolla, CA, USA.
  • Zoma A; Division of Dermatology, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, Philadelphia, PA, USA.
  • Bernatsky S; Lanarkshire Centre for Rheumatology, Hairmyres Hospital, Scotland, UK.
  • Khamashta M; Division of Rheumatology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
  • Jacobsen S; Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, King's College London School of Medicine, London, UK.
  • Buyon JP; Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Dooley MA; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY, USA.
  • Vollenhoven RV; Division of Rheumatology and Immunology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
  • Ginzler E; Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, Netherlands.
  • Stoll T; Free University (VU) Amsterdam, Amsterdam, Netherlands.
  • Peschken C; Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands.
  • Jorizzo JL; Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA.
  • Callen JP; Department of Rheumatology, Kantonsspital, Schaffhausen, Switzerland.
  • Lim S; Department of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Inanc M; Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.
  • Kamen DL; Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
  • Rahman A; Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, USA.
  • Steinsson K; Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
  • Franks AG; Division of Rheumatology, Medical University of South Carolina, Charleston, SC, USA.
Lupus ; 30(8): 1283-1288, 2021 Jul.
Article in En | MEDLINE | ID: mdl-33957797
ABSTRACT

OBJECTIVE:

Anti-beta 2 glycoprotein I IgA is a common isotype of anti-beta 2 glycoprotein I in SLE. Anti-beta 2 glycoprotein I was not included in the American College of Rheumatology (ACR) SLE classification criteria, but was included in the Systemic Lupus International Collaborating Clinics (SLICC) criteria. We aimed to evaluate the prevalence of anti-beta 2-glycoprotein I IgA in SLE versus other rheumatic diseases. In addition, we examined the association between anti-beta 2 glycoprotein I IgA and disease manifestations in SLE.

METHODS:

The dataset consisted of 1384 patients, 657 with a consensus physician diagnosis of SLE and 727 controls with other rheumatic diseases. Anti-beta 2 glycoprotein I isotypes were measured by ELISA. Patients with a consensus diagnosis of SLE were compared to controls with respect to presence of anti-beta 2 glycoprotein I. Among patients with SLE, we assessed the association between anti-beta 2 glycoprotein I IgA and clinical manifestations.

RESULTS:

The prevalence of anti-beta 2 glycoprotein I IgA was 14% in SLE patients and 7% in rheumatic disease controls (odds ratio, OR 2.3, 95% CI 1.6, 3.3). It was more common in SLE patients who were younger patients and of African descent (p = 0.019). Eleven percent of SLE patients had anti-beta 2 glycoprotein I IgA alone (no anti-beta 2 glycoprotein I IgG or IgM). There was a significant association between anti-beta 2 glycoprotein I IgA and anti-dsDNA (p = 0.001) and the other antiphospholipid antibodies (p = 0.0004). There was no significant correlation of anti-beta 2 glycoprotein I IgA with any of the other ACR or SLICC clinical criteria for SLE. Those with anti-beta 2 glycoprotein I IgA tended to have a history of thrombosis (12% vs 6%, p = 0.071), but the difference was not statistically significant.

CONCLUSION:

We found the anti-beta 2 glycoprotein I IgA isotype to be more common in patients with SLE and in particular, with African descent. It could occur alone without other isotypes.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Erythematosus, Systemic Type of study: Diagnostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Lupus Journal subject: REUMATOLOGIA Year: 2021 Document type: Article Affiliation country: Egypt
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Erythematosus, Systemic Type of study: Diagnostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Lupus Journal subject: REUMATOLOGIA Year: 2021 Document type: Article Affiliation country: Egypt